Antihypertensive therapy in diabetes mellitus: Insights from ALLHAT and the Blood Pressure-Lowering Treatment Trialists' Collaboration meta-analysis

Journal of Human Hypertension

Volumn 19, Issue 11, 2005, Pages 851-853

  Varughese, G I ^a   Lip, G Y H ^a  

^a CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; PLACEBO; THIAZIDE DIURETIC AGENT;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL STUDY; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DIET THERAPY; DISEASE ASSOCIATION; DRUG EFFICACY; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; META ANALYSIS; MORTALITY; NOTE; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK REDUCTION; STROKE; SYSTEMATIC REVIEW; THROMBOSIS;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTENSION; META-ANALYSIS;

EID: 27844563671     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001926     Document Type: Note

References (31)

1. Willaims B et al British Hypertension Society. Guidelines for management of hypertension: Report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18(3): 139-185.
2. He FJ, MacGregor GA. Cost of poor pressure control in the UK: 62000 unnecessary deaths per year. J Hum Hypertens 2003; 17: 455-457.
3. Hippisley-Cox J, Pringle M. Prevalence, care and outcomes for patients with diet-controlled diabetes in general practice: Cross-sectional survey. Lancet 2004; 363: 423-428.
4. Contreras F et al. Diabetes and hypertension physiopathology and therapeutics. J Hum Hypertens 2000; 14: S26-S31.
5. Jonas M et al. Hospital and 1-year outcome after acute myocardial infarction in patients with diabetes mellitus and hypertension. J Hum Hypertens 2003; 17: 665-670.
6. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.
7. Hansson L et al HOT Study Group. Effects of intensive blood pressure-lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-1762.
8. Whelton PK et al ALLHAT Collaborative Research Group. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165(12): 1401-1409.
9. Beevers DG, Lee KW, Lip GYH. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): ALL predictable and no big surprise out of a HAT? J Hum Hypertens 2003; 17: 367-372.
10. Turnbull F et al Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: Results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165(12): 1410-1419.
11. Stehouwer CD et al. Increased urine albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with the risk of death. Diabetes 2002; 51: 1157-1165.
12. Bautista LE. Inflammation, endothelial dysfunction, and the risk of high blood pressure: Epidemiologic and biological evidence. J Hum Hypertens 2003; 17: 223-230.
13. Boero R et al. How well are hypertension and albuminuria treated in type II diabetic patients ? J Hum Hypertens 2003; 17: 413-418.
14. Parving HH et al Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
15. Bakris GL et al. Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: A randomised multicentre pilot study. J Hum Hypertens 2002; 16: 185-191.
16. Bakris G, White D. Effects of an ACE inhibitor combined with a calcium channel blocker on progression of diabetic nephropathy. J Hum Hypertens 1997; 11: 35-38.
17. Lewis EJ et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
18. Tatti P et al. Outcome of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabet Care 1998; 21: 597-603.
19. Mogensen CE et al. Randomized controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440-1444.
20. Chin BS, Lip GYH. Blockade of the renin-angiotensin-aldosterone system with combination angiotensin receptor antagonist and ACE inhibitor therapy: Observations from Val-HeFT and CALM. J Hum Hypertens 2001; 15: 89-92.
21. Nakao N et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 2003; 361: 117-124.
22. Lip GYH, Beevers DG. More evidence on blocking the renin-angiotensin-aldosterone system in cardiovascular disease and the long-term treatment of hypertension: Data from recent clinical trials (CHARM, EUROPA, ValHEFT, HOPE-TOO and SYST-EUR2). J Hum Hypertens 2003; 17(11): 747-750.
23. Benjamin EJ et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994; 271(11): 840-844.
24. McFarlane SI, Sica DA, Sewers JR. Stroke in patients with diabetes and hypertension. J Clin Hypertens 2005; 7(5): 286-292.
25. Sowers JR, Stump CS. Insights into the biology of diabetic vascular disease: What's new? Am J Hypertens 2004; 17S: 2-6.
26. Freestone B, Beevers DG, Lip GY. The renin-angiotensin-aldosterone system in atrial fibrillation: A new therapeutic target? J Hum Hypertens 2004; 18(7): 461-465.
27. Healey JS et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A meta-analysis. J Am Coll Cardiol 2005; 45: 1832-1839.
28. Paradis P et al. Over expression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci 2000; 18: 931-936.
29. Leri A et al. Inhibition of p53 function prevents renin-angiotensin system activation and stretch-mediated myocyte apoptosis. Am J Pathol 2000; 157(3): 843-857.
30. Daly CA et al. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: Results from the PERSUADE substudy. Eur Heart J 2005; 26(14): 1369-1378.
31. Varughese GI, Tomson J, Lip GY. Type 2 diabetes mellitus: A cardiovascular perspective. Int J Clin Pract 2005; 59(7): 798-816.